Coherus Oncology CHRS
NASDAQ CHRS
$0.99 -0.08 (-7.48%)
At close: Oct 16, 2026 · 4:00 PM EDT

Coherus Oncology (CHRS) Long-Term Debt Repayments (2022)

Updated

Coherus Oncology (CHRS) posted Long-Term Debt Repayments of $233.19 million for FY2025, down 10.4% from $260.39 million in FY2024.

Analysis

Coherus Oncology (CHRS) Long-Term Debt Repayments (2022) Analysis & Trends

Since FY2020, Coherus Oncology has reported Long-Term Debt Repayments for 5 years.

  • Annual Long-Term Debt Repayments shows a five-year compound annual growth rate of 259.4% (FY2020 to FY2025).
  • The FY2025 figure stands as the lowest annual Long-Term Debt Repayments since FY2022.
  • Business Quant data shows CHRS's Long-Term Debt Repayments at $260.39 million in FY2024, $109 million in FY2022 and $672,000 in FY2021 (+72.8%).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) LT Debt Repayment (Qtr)
1 Eli Lilly 1,122.91 Bn 1,091.50 Bn 19.71 Bn 873.00 Mn
2 Johnson & Johnson 615.09 Bn 533.62 Bn 17.26 Bn 1.00 Mn
3 AbbVie 504.75 Bn 477.86 Bn 12.70 Bn 2.00 Bn
4 Merck 360.18 Bn 314.55 Bn 12.21 Bn 5.00 Mn
5 Novartis Ag 292.05 Bn 256.04 Bn 11.24 Bn 20.00 Mn
6 Astrazeneca 256.09 Bn 229.78 Bn 12.86 Bn 2.46 Bn
7 Amgen 233.63 Bn 189.02 Bn 7.24 Bn -
8 Gilead Sciences 194.49 Bn 168.69 Bn 6.22 Bn 17.00 Mn
9 Pfizer 168.35 Bn 114.99 Bn 10.94 Bn -
10 Coherus Oncology 155.59 Mn -480.55 Mn 10.07 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2022 -81.75 Mn
Mar 31, 2022 190.75 Mn
API Access

Coherus Oncology Long-Term Debt Repayments API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=long-term-debt-repayments&ticker=CHRS&period=max&api_key=YOUR_API_KEY